Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, Argos Therapeutics to Collaborate on Patient Response to Immunotherapies

NEW YORK (GenomeWeb) – Immuno-oncology firm Argos Therapeutics has announced a research agreement with Seattle-based Adaptive Biotechnologies to study patient response to investigational immunotherapies.

Adaptive combines high-throughput sequencing and bioinformatics to profile T- and B-cell receptors. Under the terms of the agreement, the Seattle-based firm will use its ImmunoSeq immune profiling assay to characterize immune response to Argo's lead product candidate, AGS-003, for metastatic renal cell carcinoma, non-small cell lung cancer, and bladder cancer. The companies will also partner on profiling genetic signatures in response to an investigational treatment for HIV or AIDS.

"Adaptive is our preferred partner because of their established expertise in offering high-throughput immune receptor repertoire characterization," Argos CSO Charles Nicolette said in a statement.

Adaptive Biotech also offers the ClonoSeq assay, a noninvasive next-generation sequencing-based test that predicts minimal residual disease in patients with blood cancers, and is developing a test for solid tumors. It acquired in vitro diagnostics firm Sequenta in January 2015.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.